Novel reaction to new cystic fibrosis medication Trikafta.
Julian StashowerPatrick CarrVirginia MillerBarrett ZlotoffPublished in: Clinical case reports (2021)
We present a novel case of an urticaria multiforme-type drug reaction to the new cystic fibrosis medication Trikafta (elexacaftor + tezacaftor + ivacaftor). Equipped with this information, clinicians may be more prepared to counsel and treat patients if they experience similar symptoms after beginning Trikafta.
Keyphrases
- cystic fibrosis
- pseudomonas aeruginosa
- end stage renal disease
- lung function
- chronic kidney disease
- adverse drug
- ejection fraction
- newly diagnosed
- healthcare
- peritoneal dialysis
- prognostic factors
- palliative care
- emergency department
- patient reported outcomes
- physical activity
- depressive symptoms
- air pollution
- electron transfer